HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial.

AbstractBACKGROUND:
The efficacy of intravesical gemcitabine was evaluated compared with repeated administration of bacille Calmette-Guérin (BCG) after BCG failure in high-risk, non-muscle-invasive bladder cancer (BC).
METHODS:
In this multicenter, prospective, randomized, phase 2 trial, eligible patients were those with high-risk non-muscle-invasive BC, failing 1 course of BCG therapy. All patients were randomly allocated to Group A, receiving intravesical gemcitabine (at a dose of 2000 mg/50 mL) twice weekly for 6 consecutive weeks and then weekly for 3 consecutive weeks at 3, 6, and 12 months, or Group B, receiving intravesical BCG (Connaught strain, 81 mg/50 mL) over a 6-week induction course and each week for 3 weeks at 3, 6, and 12 months. Outcome measures were recurrence rate, time to first recurrence, and progression rate. Treatment-related complications were also evaluated.
RESULTS:
Eighty participants were enrolled, 40 for each group 52.5% in Group A developed disease recurrence versus 87.5% of those in Group B (P = .002). There was no statistically significant difference in mean time to the first recurrence (Group A, 3.9 months; Group B, 3.1 months; P = .09). Kaplan-Meier analysis of 2-year recurrence-free survival showed significant differences between Group A and B (19% and 3%, respectively, P < .008). Seven of 21 (33%) patients in Group A and 13 of 35 (37.5%) patients in Group B had disease progression and underwent radical cystectomy (P = .12). Both intravesical administrations were generally well tolerated.
CONCLUSIONS:
Gemcitabine might represent a second-line treatment option after BCG failure in high-risk non-muscle-invasive BC patients.
AuthorsGiuseppe Di Lorenzo, Sisto Perdonà, Rocco Damiano, Adriana Faiella, Francesco Cantiello, Sandro Pignata, Paolo Ascierto, Ester Simeone, Marco De Sio, Riccardo Autorino
JournalCancer (Cancer) Vol. 116 Issue 8 Pg. 1893-900 (Apr 15 2010) ISSN: 0008-543X [Print] United States
PMID20162706 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)
Copyright(c) 2010 American Cancer Society.
Chemical References
  • Antimetabolites, Antineoplastic
  • BCG Vaccine
  • Deoxycytidine
  • Gemcitabine
Topics
  • Administration, Intravesical
  • Aged
  • Antimetabolites, Antineoplastic (administration & dosage)
  • BCG Vaccine (administration & dosage, adverse effects, therapeutic use)
  • Deoxycytidine (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
  • Female
  • Humans
  • Male
  • Retreatment
  • Treatment Failure
  • Urinary Bladder Neoplasms (pathology, therapy)
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: